Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma to Announce Third Quarter 2015 Financial Results, Host Conference Call and Live Webcast on November 9, 2015
Zosano Pharma to Announce Third Quarter 2015 Financial Results, Host Conference Call and Live Webcast on November 9, 2015 FREMONT, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage specialty pharmaceutical company, announced today that it will
View HTML
Toggle Summary Zosano Pharma Announces Positive Phase 1 Results for Its ZP-Triptan Patch Program for Treatment of Migraine
ZP-Triptan Patch is Well-Tolerated and Achieves Rapid Absorption With Potential for Fast Relief Alternative for Migraine Patients
View HTML
Toggle Summary Zosano Pharma Announces Positive Phase 2 Results for Its ZP-Glucagon Patch Program for Treatment of Severe Hypoglycemia
Zosano's ZP-Glucagon Patch Represents Potentially Superior Therapeutic Delivery Option for Patients With Type 1 Diabetes
View HTML
Toggle Summary Zosano Pharma Resumes Development of Weekly ZP-PTH Treatment for Severe Osteoporosis
Company Announces Discontinuation of Development of Daily ZP-PTH and Terminates Collaboration With Eli Lilly and Company Zosano to Host Webcast and Conference Call Today at 5:00 p.m. ET FREMONT, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) announced today that
View HTML
Toggle Summary Zosano Pharma to Present at the Ladenburg Thalmann 2015 Healthcare Conference
FREMONT, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) announced today that Vikram Lamba, Chief Executive Officer, will provide a company overview at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015.
View HTML
Toggle Summary Zosano Pharma Announces New Executive Appointment and Management Change
FREMONT, Calif., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver drug formulations through the skin, today announced management changes
View HTML
Toggle Summary Zosano Pharma Completes Enrollment in Phase 1 Study for Microneedle Patch Delivery of Zolmitriptan for the Treatment of Migraine
FREMONT, Calif., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ: ZSAN), a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver therapeutics conveniently through the skin for the treatment of a variety
View HTML
Toggle Summary Zosano Pharma Reports Second Quarter 2015 Financial Results
FREMONT, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver drug formulations through the skin, today announced financial results for
View HTML
Toggle Summary Zosano Pharma Expands Clinical & Regulatory Teams With Three Strategic Hires
FREMONT, Calif., July 13, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) announced today important leadership additions with the hiring of Donald Kellerman, Pharm.D. as Vice President, Clinical Development; David Zhang, Ph.D. as Executive Director, Biostatistics and Data
View HTML
Toggle Summary Zosano Pharma Announces Discontinuation of Novo Nordisk GLP-1 Patch Collaboration
FREMONT, Calif., July 6, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN) announced today that Novo Nordisk (NVO) has notified Zosano of its intention to discontinue the collaboration agreement related to development of a transdermal presentation of select NVO glucagon-like
View HTML